Available Technologies


283 available technologies

Direct Profiling of Proteins in Diseased Tissue by Mass Spectrometry for Assessment of Disease Classification, Development and Treatment

Methods and apparatuses for analyzing proteins and other biological materials and xenobiotics within a sample. A specimen is generated, which may include an energy absorbent matrix. The specimen is struck with laser beams such that the specimen releases proteins. The atomic mass of the released proteins over a range of atomic masses is measured. An atomic mass window of interest within the range of atomic masses is analyzed to determine the spatial arrangement of specific proteins within the sample, and those specific proteins are identified as a function of the spatial arrangement. By analyzing the proteins, one may monitor and classify disease within a sample.Australia Patent 2002362961

Neutralizing Human Monoclonal Antibody Against Respiratory Syncytial Virus

The present invention is directed to particular human monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of respiratory syncytial virus infections. In particular, these antibodies may neutralize RSV. Also disclosed are improved methods for producing monoclonal antibodies.

Plasmid Based Reverse Genetics for Reovirus

Scientists at Vanderbilt have developed an entirely plasmid-based system to better utilize reoviruses as a research tool. The system allows for generating a reovirus entirely from cloned cDNAs comprising three steps involving fairly well-known techniques.

Optical Assay of Protein Interactions

This invention provides bioluminescence resonance energy transfer (BRET) system that comprises four parts: 1) a bioluminescent protein that has luciferase activity; 2) an acceptor fluorophore that can accept the energy from the bioluminescent protein when they are associated, in the presence of the appropriate substrate; 3) a modulator that influences the proximity or the orientation of the bioluminescent protein and the fluorophore, and 4) an appropriate substrate to activate the luciferase activity of the bioluminescent protein. The components of this system interact to influence the spatial relationship between the bioluminescent protein and the fluorophore, that is demonstrated by the light emission from the system. The modulator can be a single entity, covalently attached to both the bioluminescent protein and the fluorophore, it can be two separate entities, each linked covalently to either the bioluminescent protein or the fluorophore, or an alternative configuration that falls within the scope of the invention. Thissystem can be used in both in vivo or in vitro assays to detect molecular changes in a wide variety of applications, and is amenable to automation. In particular, it is useful for assaying protein interactions, enzyme activities and the concentration of analytes or signaling molecules in cells or in solution.

Promotion of Stem Cells to Cardiomyocytes

Vanderbilt researchers have discovered specific morphogens that can promote differentiation of embryonic stem cells to cardiomyocytes. In addition when these morphogens are added to stem cells during differentiation a 10 to 20 fold increase is seen in cardiomyocyte formation. Thus addition of such morphogens may prove to be a valid therapy for cardiac repair and regeneration.

A Two Stage ES Cell Differentiation Screen

Vanderbilt researchers have identified compounds that selectively differentiate stem cells into cardiomyocytes by perturbing key pathways. Medicinal chemistry is currently underway to develop lead compounds that maybe used for the treatment of damaged cardiac muscle.

Mouse ES Stem Cell Line Marking Cardiomyocytes

This is a genetically engineered mouse ES stem cell line marking cardiomyocytes with red fluorescent protein (RFP). These cells have been used in high-throughput screens by Vanderbilt researchers for pro-cardiogenic factors. In addition the construct used in this cell line could be used to mark the cardiac progeny of transplanted stem cells, generate stable human ES cell lines, or engineer iPS for cardiac lineage studies.

Variants of Cyan Fluorescent Protein with Improved Fluorescent Properties

Dr. Piston's group has generated a variant of the enhanced cyan fluorescent protein (ECFP) that has improved brightness, more resistance to photo-bleaching and a fluorescence lifetime that is best fit by a single exponential.

Screening Test for ACE or Vasopeptidase Inhibitor Associated Angioedema

Angioedema is a life-threatening and unpredictable side effect of angiotensin converting enzyme (ACE) inhibitors and ACE/Neutral endopeptidase (NEP) inhibitors, drugs aimed at reducing cardiovascular mortality associated with a variety of disease states. This technology permits the identification of individuals at risk for developing this angioedemic condition as a result of taking ACE inhibitors or NEP inhibitors. The patents and patent applications claim biological markers, diagnostic methods and kits.

Carboxylic Acid Amides as Selective COX-2 Inhibitors

A method of treating animals having cancer by administration of secondary amide derivatives of various COOH-containing drugs, such as COOH-containing NSAIDs, for instance, indomethacin.

Selective Reversible Cyclooxygenase-2 Inhibitors

A method of altering specificity of cyclooxygenase-inhibiting compounds that have a COOH moiety by changing the various COOH containing compounds, such as indomethacin, into ester derivatives or into secondary amide derivatives.

ARF and ARF Mimics to Inhibit Myc Protein Function

The c-Myc oncogene is bound by p19Arf, which inhibits c-Myc's ability to transform cells while augmenting apoptosis. This provides the basis for screening assays that examine the ability of various candidate substances to promote p19Arf interactions, or to substitute therefor.

Live Attenuated Coronavirus Vaccines

The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.

Featured Video

Vanderbilt Patent Activity

View Vanderbilt University Patents

CTTC on Twitter